Cardiac amyloidosis is underrecognized in patients with heart failure; however, recent improvements in the understanding of this disease have led to developments in diagnosis and treatment. Cardiac ...

Please provide your email address to receive an email when new articles are posted on . A new expert consensus decision pathway published by the American College of Cardiology highlights the ...

Healio spoke with Joban Vaishnav, MD, director of the Johns Hopkins Comprehensive Amyloidosis Center, about the process of diagnosing amyloidosis, the importance of multidisciplinary care in patients ...

FRANKFORD (WPVI) -- Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being identified more and more. For Elsie McGruder, the first sign ...

For asymptomatic patients diagnosed with early-stage transthyretin amyloid cardiomyopathy (ATTR-CM), it can take just a few years to progress to clinical heart failure or other cardiovascular ...

AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...

It is possible for transthyretin amyloid cardiomyopathy (ATTR-CM, also called cardiac ATTR amyloidosis) to be reversed with antibody treatment, as suggested by rare cases of patients who had their ...

Findings showed treatment with D-VCd significantly improved MOD-PFS and OS vs treatment with VCd. The Food and Drug Administration (FDA) has granted traditional approval to Darzalex Faspro ® ...

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...